fashion -WSS

fashion

author：focus 2025-09-27 09:45:03 - browse：95

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Australia’s approach to dialysis celebrates life

Wikipedia

entertainment

WSS

Nonprofit, backed by Microsoft, to certify AI tools in health care

FDA early review: GLP

Profiling embryos to choose those with higher IQs is almost a reality

JPM pitch from hospitals? Revenue streams outside of patient care

A preacher's new calling: Diversifying neuroscience research

FDA early review: GLP

focus

fashion

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Departing Stanford president retracts two papers

Medicare proposal to cover medical devices draws a mixed reaction

Feds fine Medicare Advantage plans for overcharging members

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Diversity in medical illustrations gets boost from Chidiebere Ibe

Medicare proposal to cover medical devices draws a mixed reaction

FDA early review: GLP

23andMe had bad news about my health. I wish a person had delivered it

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

explore

How to make Best Hospitals ratings actually useful for patients

AstraZeneca challenges Medicare drug negotiation program

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Life science postdocs should get big pay hike, NIH panel says

What do new weight loss drugs mean for bariatric surgery?

Arena BioWorks launches in Cambridge to speed drug discovery

Wikipedia

knowledge

entertainment

knowledge